Natasha Rekhtman

40.2k total citations · 9 hit papers
181 papers, 13.3k citations indexed

About

Natasha Rekhtman is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Natasha Rekhtman has authored 181 papers receiving a total of 13.3k indexed citations (citations by other indexed papers that have themselves been cited), including 121 papers in Pulmonary and Respiratory Medicine, 105 papers in Oncology and 36 papers in Molecular Biology. Recurrent topics in Natasha Rekhtman's work include Lung Cancer Treatments and Mutations (87 papers), Lung Cancer Research Studies (65 papers) and Lung Cancer Diagnosis and Treatment (43 papers). Natasha Rekhtman is often cited by papers focused on Lung Cancer Treatments and Mutations (87 papers), Lung Cancer Research Studies (65 papers) and Lung Cancer Diagnosis and Treatment (43 papers). Natasha Rekhtman collaborates with scholars based in United States, Japan and Canada. Natasha Rekhtman's co-authors include Marc Ladanyi, William D. Travis, Maria E. Arcila, Mark G. Kris, Gregory J. Riely, Maureen F. Zakowski, Camelia S. Sima, Helena A. Yu, André L. Moreira and Charles M. Rudin and has published in prestigious journals such as Nature, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Natasha Rekhtman

176 papers receiving 13.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR -Mutant Lung Cancers

2013 1.9k citations Helena A. Yu, Maria E. Arcila et al. Clinical Cancer Research profile →
The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015

2021 752 citations Natasha Rekhtman, William D. Travis et al. Journal of Thoracic Oncology profile →
In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system

2014 468 citations Natasha Rekhtman, Elisa de Stanchina et al. profile →
Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping

2015 423 citations Paul K. Paik, Alexander Drilon et al. Cancer Discovery profile →
EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics

2013 348 citations Maria E. Arcila, Khédoudja Nafa et al. Molecular Cancer Therapeutics profile →
Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial

2016 327 citations Alexander Drilon, Natasha Rekhtman et al. profile →
Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like Subsets

2016 325 citations Natasha Rekhtman, M. Catherine Pietanza et al. Clinical Cancer Research profile →
SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization

2020 301 citations Marina K. Baine, W. Victoria Lai et al. Journal of Thoracic Oncology profile →
Regenerative lineages and immune-mediated pruning in lung cancer metastasis

2020 251 citations Ashley M. Laughney, Jing Hu et al. Nature Medicine profile →

Peers

Countries citing papers authored by Natasha Rekhtman

Since Specialization

Citations

This map shows the geographic impact of Natasha Rekhtman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Natasha Rekhtman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Natasha Rekhtman more than expected).

Fields of papers citing papers by Natasha Rekhtman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Natasha Rekhtman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Natasha Rekhtman. The network helps show where Natasha Rekhtman may publish in the future.

Co-authorship network of co-authors of Natasha Rekhtman

This figure shows the co-authorship network connecting the top 25 collaborators of Natasha Rekhtman. A scholar is included among the top collaborators of Natasha Rekhtman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Natasha Rekhtman. Natasha Rekhtman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Correlation of Histologic Features with Gene Alterations in Pleural Mesothelioma 2025 ·Modern Pathology ·(unknown), Soo‐Ryum Yang, Kay See Tan, Prasad S. Adusumilli, Francis M. Bodd, Anita S. Bowman, Jason C. Chang, Michael Offin, (unknown), Natasha Rekhtman, Valerie W. Rusch, William D. Travis, Marjorie G. Zauderer, Marc Ladanyi, Jennifer L. Sauter	2
2	First Report of Response to Tarlatamab in a Patient With DLL3-Positive Pulmonary Carcinoid: Case Report 2024 ·JTO Clinical and Research Reports ·Alissa J. Cooper, Natasha Rekhtman, Marina K. Baine, (unknown), (unknown), Ryan D. Gentzler	2
3	A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer 2024 ·Clinical Cancer Research ·Noura J. Choudhury, W. Victoria Lai, Alex Makhnin, Glenn Heller, Juliana Eng, Bob T. Li, Isabel R. Preeshagul, (unknown), Michael Offin, Kenneth Ng, Paul K. Paik, (unknown), Michelle S. Ginsberg, Yvonne Lau, Xinyuan Zhang, Marina K. Baine, Natasha Rekhtman, Charles M. Rudin	14
4	Prognostic Implications of Small Cell Lung Cancer Transcriptional Subtyping for CNS Metastases 2024 ·JCO Precision Oncology ·Kathryn R. Tringale, Anna Skakodub, Jacklynn V. Egger, (unknown), Yao Yu, Daniel R. Gomez, Andreas Rimner, Bob T. Li, Yoshiya Yamada, Jessica Wilcox, Nelson S. Moss, Brandon S. Imber, Natasha Rekhtman, Marina K. Baine, Charles M. Rudin, Luke Pike	2
5	CT-based Radiogenomic Analysis of Clinical Stage I Lung Adenocarcinoma with Histopathologic Features and Oncologic Outcomes 2022 ·Radiology ·Rocío Pérez-Johnston, José de Arimateia Batista Araújo-Filho, James G. Connolly, Raul Caso, Karissa Whiting, Kay See Tan, Jian Zhou, Peter Gibbs, Natasha Rekhtman, Michelle S. Ginsberg, David R. Jones	59
6	Invasive Mucinous Adenocarcinomas With Spatially Separate Lung Lesions: Analysis of Clonal Relationship by Comparative Molecular Profiling 2021 ·Journal of Thoracic Oncology ·Soo‐Ryum Yang, Jason C. Chang, Charles Leduc, Kay See Tan, Snjezana Doğan, Ryma Benayed, Laetitia Borsu, Michael Offin, Alexander Drilon, William D. Travis, Maria E. Arcila, Marc Ladanyi, Natasha Rekhtman	20
7	Are there imaging characteristics that can distinguish separate primary lung carcinomas from intrapulmonary metastases using next-generation sequencing as a gold standard? 2021 ·Lung Cancer ·José de Arimateia Batista Araújo-Filho, Jason C. Chang, María Mayoral, Andrew J. Plodkowski, Rocío Pérez-Johnston, Stephanie Lobaugh, Junting Zheng, Valerie W. Rusch, Natasha Rekhtman, Michelle S. Ginsberg	5
8	Rapid EGFR Mutation Detection Using the Idylla Platform 2020 ·Journal of Molecular Diagnostics ·Amir Momeni Boroujeni, Paulo Salazar, Tao Zheng, Nana Yaa Mensah, Ivelise Rijo, Snjezana Doğan, (unknown), Christine Moung, Chad Vanderbilt, Jamal Benhamida, Jason C. Chang, William D. Travis, Natasha Rekhtman, Marc Ladanyi, Khédoudja Nafa, Maria E. Arcila	19
9	Regenerative lineages and immune-mediated pruning in lung cancer metastasis breakdown → 2020 ·Nature Medicine ·Ashley M. Laughney, Jing Hu, Nathaniel R. Campbell, Samuel F. Bakhoum, Manu Setty, Vincent‐Philippe Lavallée, Yubin Xie, Ignas Masilionis, Ambrose Carr, Sanjay Kottapalli, Viola Allaj, Marissa S. Mattar, Natasha Rekhtman, João B. Xavier, Linas Mažutis, John T. Poirier, Charles M. Rudin, Dana Pe’er, Joan Massagué	251
10	A Performance Comparison of Commonly Used Assays to Detect RET Fusions 2020 ·Clinical Cancer Research ·Soo‐Ryum Yang, Umut Aypar, Ezra Y. Rosen, Douglas A. Mata, Ryma Benayed, Kerry Mullaney, Gowtham Jayakumaran, Yanming Zhang, Denise Frosina, Alexander Drilon, Marc Ladanyi, Achim A. Jungbluth, Natasha Rekhtman, Jaclyn F. Hechtman	50
11	Comprehensive Next-Generation Sequencing Unambiguously Distinguishes Separate Primary Lung Carcinomas From Intrapulmonary Metastases: Comparison with Standard Histopathologic Approach 2019 ·Clinical Cancer Research ·Jason C. Chang, Deepu Alex, Matthew J. Bott, Kay See Tan, Venkatraman Seshan, (unknown), Jennifer L. Sauter, Darren J. Buonocore, Chad Vanderbilt, Sounak Gupta, Patrice Desmeules, Francis M. Bodd, Gregory J. Riely, Valerie W. Rusch, David R. Jones, Maria E. Arcila, William D. Travis, Marc Ladanyi, Natasha Rekhtman	67
12	PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer 2016 ·Clinical Cancer Research ·Benjamin H. Lok, Eric E. Gardner, Valentina E. Schneeberger, Ai Ni, Patrice Desmeules, Natasha Rekhtman, Elisa de Stanchina, Beverly A. Teicher, Nadeem Riaz, Simon N. Powell, John T. Poirier, Charles M. Rudin	261
13	Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like Subsets breakdown → 2016 ·Clinical Cancer Research ·Natasha Rekhtman, M. Catherine Pietanza, Matthew D. Hellmann, Jarushka Naidoo, Arshi Arora, Helen Won, Darragh Halpenny, Hangjun Wang, Shaozhou K. Tian, Anya M. Litvak, Paul K. Paik, Alexander Drilon, Nicholas D. Socci, John T. Poirier, Ronglai Shen, Michael F. Berger, André L. Moreira, William D. Travis, Charles M. Rudin, Marc Ladanyi	325
14	An Expression Signature as an Aid to the Histologic Classification of Non–Small Cell Lung Cancer 2016 ·Clinical Cancer Research ·Luc Girard, Jaime Rodriguez‐Canales, Carmen Behrens, Debrah M. Thompson, Ihab W. Botros, Hao Tang, Yang Xie, Natasha Rekhtman, William D. Travis, Ignacio I. Wistuba, John D. Minna, Adi F. Gazdar	132
15	Next-Generation Sequencing of Stage IV Squamous Cell Lung Cancers Reveals an Association of PI3K Aberrations and Evidence of Clonal Heterogeneity in Patients with Brain Metastases 2015 ·Cancer Discovery ·Paul K. Paik, Ronglai Shen, Helen Won, Natasha Rekhtman, Lu Wang, Camelia S. Sima, Arshi Arora, Venkatraman Seshan, Marc Ladanyi, Michael F. Berger, Mark G. Kris	111
16	Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping breakdown → 2015 ·Cancer Discovery ·Paul K. Paik, Alexander Drilon, Pang‐Dian Fan, Helena A. Yu, Natasha Rekhtman, Michelle S. Ginsberg, Laetitia Borsu, Nikolaus Schultz, Michael F. Berger, Charles M. Rudin, Marc Ladanyi	423
17	Using frozen section to identify histological patterns in stage I lung adenocarcinoma of ≤3 cm: accuracy and interobserver agreement 2014 ·Histopathology ·Yi‐Chen Yeh, Jun‐ichi Nitadori, Kyuichi Kadota, Akihiko Yoshizawa, Natasha Rekhtman, André L. Moreira, Camelia S. Sima, Valerie W. Rusch, Prasad S. Adusumilli, William D. Travis	112
18	EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics breakdown → 2013 ·Molecular Cancer Therapeutics ·Maria E. Arcila, Khédoudja Nafa, Jamie E. Chaft, Natasha Rekhtman, Christopher Lau, Boris Reva, Maureen F. Zakowski, Mark G. Kris, Marc Ladanyi	348
19	Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR / KRA S and Presence of PIK3CA / AKT1 Mutations 2012 ·Clinical Cancer Research ·Natasha Rekhtman, Paul K. Paik, Maria E. Arcila, Laura J. Tafe, Geoffrey R. Oxnard, André L. Moreira, William D. Travis, Maureen F. Zakowski, Mark G. Kris, Marc Ladanyi	289
20	PU.1 and pRB Interact and Cooperate To Repress GATA-1 and Block Erythroid Differentiation 2003 ·Molecular and Cellular Biology ·Natasha Rekhtman, Kevin S. Choe, Igor Matushansky, Stuart Murray, Tomáš Stopka, Arthur I. Skoultchi	85

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact